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Purpose: We conducted a phase II study of carboplatin and irino-
tecan in patients with advanced non-small cell lung cancer
(NSCLC). In addition, we studied the correlation between certain
genotypes of enzymes involved in irinotecan metabolism with effi-
cacy and toxicity.
Patients and Methods: Patients with stage IIIB, IV, or recurrent
NSCLC received a combination of irinotecan and carboplatin every
3 weeks at a dose of 200 mg/m2 and area under the curve of 5.
Pharmacogenomic analysis was performed on several genes of
interest (ABCB1, CYP3A4*1B, ERCC2, GSTP1, UGT1A1*28, and
XRCC1).
Results: Forty-two patients enrolled between December 2001 and
January 2004. Six patients achieved partial responses (14%), and 19
(45%) had stable disease. The median progression-free survival was
6.9 months. The median overall survival was 11.7 months, with
1-year overall survival of 42%. The most common toxicities were
hematologic; grade 3 or 4 neutropenia was experienced by 26
patients (62%) during treatment, and 15 patients (36%) experienced
grade 3 or 4 thrombocytopenia. The homozygous UGT1A1*28 (7/7)
genotype was associated with grade 4 neutropenia in three of four
patients (75%), but only eight out of 30 (27%) with 6/6 or 6/7
genotypes experienced grade 4 neutropenia (p  0.09). None of the
14 patients with the GSTP1 I105V A/A genotype had a partial
response, as opposed to five out of 19 (26%) of those with the G/A
or G/G genotypes (p  0.057).
Conclusion: The combination of carboplatin and irinotecan is an
active combination in NSCLC, with response rates comparable with
other platinum-containing doublets. Further studies with irinotecan
should incorporate prospective pharmacogenomic analysis to iden-
tify markers for response and toxicity.
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(J Thorac Oncol. 2006;1: 972–978)
There will be an estimated 172,570 new cases of lungcancer diagnosed in 2005, and an estimated 163,510
patients will die of lung cancer in the same year.1 Cisplatin-
based chemotherapy has been shown to lengthen survival
time in these patients and improve quality of life.2 Carbopla-
tin-based regimens seem to provide clinically similar survival
compared with cisplatin-containing regimens, but they may be
associated with less morbidity.3–5 Despite the recent advances,
the overall survival for patients with metastatic NSCLC contin-
ues be poor, with 1-year survival less than 40%.6,7
Irinotecan (Camptosar) is a camptothecin-derived com-
pound whose active metabolite, SN-38, interacts with topo-
isomerase I by stabilizing the complex formed with DNA.8 In
addition to this novel cytotoxic mechanism, irinotecan differs
from other available chemotherapeutic agents in that multi-
drug-resistant cell lines retain sensitivity to irinotecan.9 It has
been approved for the treatment of metastatic colon cancer in
the United States. As a single agent, the response rates in
NSCLC vary from 15 to 34%.10–13
Preclinical studies suggest that irinotecan and platinum
compounds act synergistically in vitro.8 Response rates as
high as 52% have been reported when irinotecan was com-
bined with cisplatin in patients with previously untreated
stage III B or IV NSCLC.14 A randomized phase III study
compared the efficacy of single-agent weekly irinotecan and
weekly irinotecan administered with cisplatin with a regimen
of cisplatin and vindesine.13 The overall response rates for the
three arms were 21, 44, and 32%, respectively, although there
were no statistically significant differences between the arms.
Carboplatin in combination with weekly irinotecan has
been shown to be tolerable in phase I studies, with dose-
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limiting toxicities of myelosuppression and diarrhea.15 Sub-
sequent phase II study of weekly administration demonstrated
a response rate of 36% in patients with advanced NSCLC in
a Japanese patient population.16 A modified schedule deliv-
ering the irinotecan every 3 weeks rather than every week
could potentially be more tolerable and convenient. Based on
the phase I study demonstrating the feasibility of administer-
ing both irinotecan and carboplatin, we conducted a phase II
study in advanced NSCLC.
There are no reliable molecular predictors of toxicity or
response to therapy in NSCLC. Irinotecan is a prodrug
(CPT-11) that is metabolized into its active form, SN-38,
when inside the cell.17 Irinotecan and SN-38 may be trans-
ported out of the cell via multidrug transporters such as
ABCB1. Irinotecan is converted into SN-38 via human car-
boxylesterases18 but can also be converted to inactive metab-
olites via CYP3A4 and CYP3A5, and SN-38 can be inacti-
vated through glucuronidation to SN-38G via UGT1A1. The
UGT1A1*28 allele provides the strongest support for a role
of pharmacogenetics in predicting toxicity from irinotecan
therapy.19,20 There are few data on carboplatin pharmacoge-
netics, but polymorphisms in DNA repair and detoxification
enzymes such as ERCC2, XRCC1, and glutathione S-trans-
ferase-Pi (GSTP1) have been associated with response to
other platinum chemotherapy agents.21–24
To determine the impact of ABCB1, CYP3A4, ERCC2,
GSTP1, UGT1A1, and XRCC1 polymorphisms on response
or toxicities from irinotecan and carboplatin, we collected
blood samples for pharmacogenetic analysis from consenting
patients.
PATIENTS AND METHODS
Patient Selection
Adult (18 years of age) patients were eligible who
had histologically documented, unidimensionally measurable
NSCLC with stage IIIB, IV, or recurrent disease. Patients
with a controlled and treated brain metastasis were eligible.
Patients could not have had prior chemotherapy for metastatic
or advanced NSCLC. Prior irradiation was allowed, provided
that at least 2 weeks had elapsed since the completion of
therapy and the patients had a measurable lesion that had not
been irradiated. Patients were required to have an ECOG
performance status of 0 to 2 and a life expectancy of at least
3 months. Laboratory requirements included proof of ade-
quate bone marrow function (absolute neutrophil count
[ANC] 1500/mm3 and platelet count 100,000/mm3) and
adequate liver (bilirubin 1.5  upper limit of normal) and
renal function (creatinine 2.0 or calculated creatinine clear-
ance of 60 mL/min if the creatinine was above 2.0).
Computed tomographic scans of the affected areas (chest,
abdomen, and/or pelvis) were required to have been done
within 4 weeks of study entry. Patients were required to be
free from uncontrolled intercurrent illness. Patients with ac-
tive second malignancies (excluding nonmelanoma skin can-
cer) were not eligible, nor were patients using or having used
phenytoin or carbamezepine within 7 days before enrollment,
because these drugs have been associated with an increased
metabolism of irinotecan. All patients signed informed con-
sent before enrollment. The protocol was reviewed and ap-
proved by the institutional review board of Washington
University School of Medicine.
Treatment and Patient Evaluation
Both irinotecan and carboplatin were administered in-
travenously every 3 weeks. The first five patients received
irinotecan at a dose of 250 mg/m2, but subsequent patients
received irinotecan at a dose of 200 mg/m2 because excessive
dose delays for neutropenia had been noted with higher doses
of irinotecan. Irinotecan was infused for 90 minutes, and then
carboplatin was given for 1 hour at a target area under the
concentration–time curve of 5. All patients received a 5-HT3
receptor antagonist before treatment for nausea prophylaxis.
Atropine (0.5 mg intravenously) was given before irinotecan
as prophylaxis against early cholinergic syndrome associated
with this agent. Patients were instructed in the use of loper-
amide for treatment of diarrhea. Routine prophylactic use of
G-CSF was not recommended.
Patients underwent weekly complete blood counts and
a complete metabolic profile at the initiation of each course of
chemotherapy. Patients also underwent physical examination
and toxicity assessment before each cycle. Assessment of
disease response was performed by computed tomographic
scan every two cycles of chemotherapy (or sooner if clini-
cally warranted). Patients could receive up to six cycles of
therapy; they were removed from the study on disease pro-
gression or if they reached unacceptable toxicity (per protocol
criteria or patient/physician opinion). Patients also left the
study if they withdrew consent or in cases of treating physi-
cian or patient request or decline in health status precluding
further therapy or follow-up.
Dose Modification
Toxicity was graded using the National Cancer Institute
common toxicity criteria (version 2.0). No treatments could
be administered unless all previous toxicities greater than or
equal to grade 2 had resolved, ANC had returned to 1500/
mm3, and platelet count had returned to 100,000/mm3. The
dose of irinotecan was reduced by 20% if the patient’s nadir
ANC in the previous cycle had been 500/mm3 for more
than 7 days or if he or she had experienced febrile neutrope-
nia. If the patient suffered a subsequent cycle with neutro-
penic fever or ANC 500/mm3 for more than 7 days,
filgrastim was allowed for subsequent cycles. If there was
still ANC 500/mm3 for more than 7 days or neutropenic
fever in subsequent cycles, the patient was removed from
study. The following modifications were made based on
diarrhea: the previous cycle toxicity must have resolved to
grade 1 or less (no more than three stools per day during
pretreatment) before initiation of the next cycle. If a patient
suffered grade 2 diarrhea (four to six stools during pretreat-
ment), subsequent cycles dose of irinotecan was reduced by
15%. If a patient suffered grade 3 diarrhea (seven or more
stools during pretreatment or a need for intravenous fluid
support), in subsequent cycles dose of irinotecan was reduced
by 25%. Diarrhea causing hemodynamic collapse (grade 4)
was cause for removal from study. For all other nonhemato-
logic toxicity, if a patient suffered grade 2 or 3 toxicity,
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subsequent doses of irinotecan were reduced by 15%. If a
patient suffered grade 4 nonhematologic toxicity (other than
diarrhea), doses of irinotecan were reduced by 25% in sub-
sequent cycles. Dose reescalation was not permitted in this
study. Carboplatin dose was not modified for toxicities during
this study.
Determination of Dose Intensity
Dose intensity, defined as the amount of drug delivered
per unit of time,25 was determined for both agents. The RDI
for irinotecan was calculated based on a reference dose of 67
mg/m2 per week (200 mg/m2 per cycle), and the carboplatin
Relative Dose Intensity (RDI) was based on the total weeks
on therapy.
Response Evaluation
Response was evaluated by Response Evaluation Cri-
teria in Solid Tumors criteria. Tumor reassessment was per-
formed by the same imaging method used to establish a
baseline at study entry. When there was disagreement regard-
ing the exact measurement and response determination, a
third-party radiologist reevaluated the computed tomographic
scans for response. Time to response was defined as the time
from the first day of therapy to the first observation of an
objective response. Duration of response was defined as the
time from the first observation of an objective response to the
first observation of progressive disease. Duration of response
was not calculated for those without response (those without
stable disease [SD] or partial response [PR]). Time to tumor
progression was defined as the time from the first day of
therapy to the first observation of progressive disease. Overall
survival was defined as the time from the first day of therapy
to death, and progression-free survival was defined as the
time from the first day of therapy to the date of documented
progression or death (whichever occured first).
Pharmacogenomic Analysis
Blood samples were collected on consenting patients (n 
38) for pharmacogenetic analysis. Genomic DNA was extracted
from 1 ml of whole blood using the Gentra PureGene Blood Kit
(Gentra, Minneapolis, MN) following the manufacturers’ instruc-
tions and was reconstituted in 10 mM Tris/1 mM EDTA (pH 7.6).
Variations in the genes of interest (ABCB1 3435CT [I1143I];
CYP3A4*1B [-392AG]; ERCC2 2251 TG [K751Q]; GSTP1
313AG [I105V]; UGT1A1*28 [(TA)7TAA]; XRCC1
1196GA [R399Q]) were analyzed using polymerase chain reac-
tion (PCR) and pyrosequencing.Analysis of theABCB1,CYP3A4,
ERCC2, and UGT1A1 variants was performed using PCR and
pyrosequencing primers as previously described.26–28 PCR primers
for GSTP1 I105V (forward: 5=-Biotin-GGTGAATGACGGCGT-
GGA-3=; reverse: 5=-CCCTTTCTTTGTTCAGCCCC-3=) and
XRCC1 R399Q (forward: 5=-Biotin-TAAGGAGTGGGTGCTG-
GACTGTC-3=; reverse: 5=-TGACTCCCCTCCAGATTCCT-3=)
were designed using Primer Express version 1.5 (ABI, Foster City,
CA). The pyrosequencing primers GSTP1 I105V: 5=-TTGGTG-
TAGATGAGGGA-3= and XRCC1 R399Q 5=-GAGGCCT-
TACCT-3= were designed using the pyrosequencing SNP Primer
Design Version 1.01 software (http://www.techsupport.
pyrosequencing.com). PCR was carried out using Amplitaq
Gold PCR master mix (ABI, Foster City, CA), 5 pmole of
each PCR primer, and 5 to 10 ng of DNA. Pyrosequencing
was performed and analyzed as previously described26 using
a pyrosequencing PSQhs96A instrument and software
(Biotage, Uppsala, Sweden).
Statistical Analysis
Data analysis of this study is mainly descriptive. The
primary objective of the study was to determine the response
rate for the combination of carboplatin and irinotecan when
given every 3 weeks to patients with stage IIIB or IV NSCLC.
Secondary objectives included determination of 1-year overall
survival and progression-free survival and toxicity and evalua-
tion of the influence of pharmacogenomic variation in the genes
involved in irinotecan or carboplatin metabolism on toxicity.
Kaplan-Meier curves were used to describe overall survival and
progression-free survival, and Fisher’s exact test was performed
to explore the possible correlation between pharmacogenomic
variation and toxicity/response.
RESULTS
Patient Demographics
Forty-two patients were enrolled between December
2001 and January 2004. The first five patients experienced
excessive hematologic toxicity resulting in multiple treatment
delays. Given this toxicity, the decision was made to reduce
the irinotecan dose to 200 mg/m2; this initial dose was given
to the subsequent 37 patients. Table 1 summarizes the patient
characteristics. Sixty-two percent were males, and median
age was 60 years (range, 33–77). Adenocarcinoma was the
TABLE 1. Baseline Characteristics of Enrolled Population
(n  42)
Total
n %
Age
Mean 60
Range 33–77
Gender
Male 26 61.9
Female 16 38.1
Histologic subtype
Adenocarcinoma 29 69
Squamous 4 10
Poorly differentiated NOS 6 14
Other 3 7
Stage at study entry
IIIB 9 21
IV 29 69
Recurrent 4 10
Performance status
0 11 26
1 28 67
2 3 7
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most common histology (69%). Most patients (79%) had
metastatic or recurrent disease, with the remainder presenting
as stage IIIB with malignant pleural effusion.
Drug Delivery
A total of 160 cycles were administered to the 42
patients (Table 2). One patient received an additional two
cycles off protocol for a total of eight cycles, and one patient
who was removed from the study per protocol after three
cycles for treatment delay received a fourth cycle off proto-
col; these patients’ toxicities from these off- protocol cycles
are included in this analysis. Thirty-two patients received two
or more cycles of chemotherapy, and 24 patients received
four or more cycles of chemotherapy. The mean RDI of
irinotecan and carboplatin were 91.2 and 92.2 percent, re-
spectively. No significant association between the RDI of
irinotecan and treatment response, progression-free survival,
and overall survival was noted.
Efficacy
Of the 42 patients enrolled, eight patients (19%) were
removed from study within the first cycle for reasons not
related to disease progression (Table 3). The remaining 34
patients were evaluable for response. No patient had a com-
plete response. Six patients achieved partial responses (14%
of the total), whereas 19 (45%) had stable disease, with an
average 47-day time to first response and 176-day duration of
response. Nine patients developed progressive disease (21%)
within the first two cycles.
Median follow- up time was 11.7 months. The median
progression-free survival was 6.9 months (95% confidence
interval (CI), 3.5–7.8), with a 1-year progression-free sur-
vival of 9.5%. The median overall survival was 11.7 months
(95% CI, 8.4–13.2), with a 1-year overall survival of 42%
(Fig. 1).
Toxicity
Grade 3 and 4 toxicities are presented in Table 4, listed
as number of patients experiencing experiencing grade 3 or 4
TABLE 2. Cycles of Chemotherapy Delivered
Number of Cycles Frequency Percent of Total
1 10 23.8
2 7 16.7
3 1 2.4
4 6 14.3
5 1 2.4
6* 17 40.5
Total 160 100
*Includes one patient who received an additional two cycles off protocol, for a total
of eight.
TABLE 3. Reasons for Patient Removal from Study in First
Cycle
Patient Reason for Removal from Study
1 Found to have new rectal cancer
2 Removed by treating physician because of decreased
performance status
3 Given radiation for palliation of hemoptysis
4 Died of gram-negative sepsis*
5 Died of transfusion-associated lung injury
6 Removed for grade 4 diarrhea*
7 Removed for grade 4 diarrhea*
8 Removed for treatment delays caused by intercurrent
myocardial infarction
*Treatment-related toxicity.
FIGURE 1. Overall survival.
Journal of Thoracic Oncology • Volume 1, Number 9, 2006 Irinotecan and Carboplatin in Advanced NSCLC
Copyright © 2006 by the International Association for the Study of Lung Cancer 975
toxicities in any cycle as their worst toxicity. In the first cycle,
one patient died of transfusion-related acute lung injury,
which was considered unrelated to treatment, and one patient
died of neutropenic sepsis and grade 4 diarrhea related to
treatment. The most common toxicities were hematologic;
grade 3 or 4 neutropenia was experienced by 26 patients
(62%) at some point in their treatment course. A total of 15
patients (36%) experienced grade 3 or 4 thrombocytopenia as
their worst toxicity. A total of 38 (of 160) cycles of delivered
chemotherapy were complicated by grade 3 neutropenia
(24%), and a total of 22 cycles (52%) were complicated by
grade 4 neutropenia.
Pharmacogenomic Analysis
Pharmacogenetic data were available for 38/42 patients
(Table 5). The homozygous UGT1A1*28 (7/7) genotype was
associated with grade 4 neutropenia in three of four patients
(75%), as opposed to eight of 30 (27%) in those with 6/6 or
6/7 genotypes, but this relationship failed to achieve statisti-
cal significance (p  0.09). None of the 14 patients with the
GSTP1 I105V A/A genotype had a partial response, as
opposed to five out of 19 (26%) of those with the G/A or G/G
genotypes, but this association did not reach statistical sig-
nificance (p  0.057). ABCB1 3435CT, CYP3A4*1B,
ERCC2 K751Q, and XRCC1 R399Q showed no significant
association with grade 4 neutropenia or PR (p 0.05). Given
the relative rarity of other toxicities in this study, correlation
between these alleles and other toxicities was not performed.
DISCUSSION
In this phase II study, the combination of irinotecan and
carboplatin administered once every 3 weeks produced a
1-year survival rate similar to what has been reported with
platinum doublets. Other investigators have also tested the
combination of a platinum compound with irinotecan using
various schemas (Table 6). None of these regimens seem to
produce superior results. Nevertheless, toxicity profiles vary
between these different regimens. It would be desirable to
identify clinical or laboratory markers that would help iden-
tify patients at risk for therapy-related toxicities and those
likely to respond to a given therapy.
We investigated multiple polymorphisms related to
irinotecan metabolism, but we failed to demonstrate the
association of any of these alleles with toxicity or response.
We did find a trend toward a correlation between therapy-
related severe neutropenia in patients homozygous for
UGT1A1*28, although given the small number of patients in
this association, it is difficult to draw firm conclusions.
UGT1A1 is involved in the metabolism of the active metab-
olite of irinotecan (SN-38), detoxifying it by glucuronidation.
The association of the UGT1A1*28 allele has been associated
with risk of neutropenia with irinotecan by others20,29 and is
part of the basis for an FDA-approved test of UGT1A1
genotype and recent changes to the Camptosar package in-
sert.30,31 Additionally, the GSTP1 gene is involved with the
detoxification of several chemotherapeutic agents, including
platinum agents,22,23 and its overexpression or overactivity is
associated with chemoresponsiveness in several tumor types,
including lung.32 We have demonstrated a trend toward
decreased response with the GSTP1 I105V A/A polymor-
phism, although this again failed to reach statistical signifi-
cance. Our inability to uncover statistically significant asso-
ciations between alleles studied and toxicity or response is
most likely a reflection of the small number of data points that
we were able to analyze in this optional portion of a study
with a limited number of subjects.
TABLE 4. Common Toxicity Criteria (CTC) Grade 3 and 4
Toxicity
Patients Experiencing as Their Worst Toxicity
CTC Grade 3 CTC Grade 4
Toxicity No. % No. %
Neutropenia 11 26 15 36
Thrombocytopenia 10 24 5 12
Anemia 9 21 1 2
Neutropenic fever 8 19
Diarrhea 2 5 3 7
Hyperglycemia 1 2
Dizziness 4 10
Dehydration 1 2
Fatigue 1 2
Nausea 5 12
Emesis 2 5
Malaise 2 5
Pain 4 10
Infection 3 7
Dyspnea 7 17
Hospitalizations occurred in 16 patients (38.1%), and phlebitis (DVT or PE)
occurred in three patients (7.1%).
TABLE 5. Genotype and Allele Frequencies for 38 Study Patients
Polymorphism n
Homozygous
Wild Type Heterozygous
Homozygous
Variant p q
ABCB1 3435CT 34 9 11 14 0.43 0.57
CYP3A4*1B 38 26 7 5 0.78 0.22
GSTP I105V 33 14 14 5 0.64 0.36
ERCC2 K751Q 31 13 14 4 0.65 0.35
XRCC1 R399Q 33 18 13 2 0.74 0.26
UGT1A1*28 34 12 18 4 0.62 0.38
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Clearly, an efficacy plateau has been reached using
doublet therapy with traditional chemotherapy agents in
NSCLC. Multiple regimens are available with comparable
therapeutic efficacy but differing toxicity profiles. Future
studies should focus on the genetic basis for predictors of
response and toxicity in individual patients, possibly by
mandatory collection of genomic material at study entry to
discover more statistically robust associations. This approach
holds the promise of tailoring drugs to patients to avoid
therapies that would produce excess toxicity and, possibly,
steering individual patients to the most effective available
therapy.
CONCLUSION
The combination of irinotecan and carboplatin in this
phase II study produced median and 1-year survival rates
similar to the results obtained with other platinum-based
doublets. Nevertheless, this regimen was associated with a
fairly significant degree of neutropenia (including febrile
neutropenia), although incidence of severe diarrhea was
lower than that reported with weekly irinotecan infusion.
Correlative pharmacogenomic analyses suggest possible re-
lationships between UGT1A1*28 and toxicity and GSTP1
I105V and response, but these relationships failed to reach
statistical significance, likely because of the small sample
size. Further studies with irinotecan should incorporate pro-
spective pharmacogenomic analysis to identify selective
markers for response and toxicity.
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